Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dynein light chain roadblock-type 2 in preparation of medicine treating kidney failure and the medicine thereof

A dynein and light chain technology, used in gene therapy, drug combinations, pharmaceutical formulations, etc., can solve the problems of impairing the anti-inflammatory properties of TGF-beta, not producing effective results, promoting nephritis, etc., and achieving control of renal fibrosis. fibrosis, preventing kidney disease, reducing the effect of kidney fibrosis

Inactive Publication Date: 2014-12-10
SHENZHEN RES INST THE CHINESE UNIV OF HONG KONG
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, after in-depth investigation, it was found that the use of these strategies did not produce the expected effective results.
This may be due to the fact that blockade of the TGF-beta signaling upstream pathway impairs the potent anti-inflammatory properties of TGF-beta and subsequently promotes renal inflammation
On the other hand, crosstalk of intracellular Smad pathways hinders strategies targeting TGF-beta and TGF-beta receptor kinases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dynein light chain roadblock-type 2 in preparation of medicine treating kidney failure and the medicine thereof
  • Application of dynein light chain roadblock-type 2 in preparation of medicine treating kidney failure and the medicine thereof
  • Application of dynein light chain roadblock-type 2 in preparation of medicine treating kidney failure and the medicine thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings. It should be emphasized that the following description is only exemplary and not intended to limit the scope of the invention and its application.

[0030] The study found that specific inhibitors of Smad3, HSP72, and HSP90 can reduce renal fibrosis. A new avenue for alternative treatment of renal fibrosis may thus be provided. The use of inhibitors targeting the TGF-beta / Smad3 signaling pathway may provide a new, effective, and safe treatment for kidney disease.

[0031] In the embodiment of the present invention, the ultrasonic microvesicle plasmid transfection technology is preferably used to transfect the shRNA plasmid inhibiting dynein light chain-2 into the kidney, and down-regulate the expression of dynein light chain-2 in kidney cells. A good effect of inhibiting dynein light chain-2 in the treatment of diabetic nephropathy can be detected.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a compound inhibiting dynein light chain roadblock-type 2 in preparation of a medicine treating kidney diseases especially kidney failure diabetes. A knockdown dynein light chain roadblock-type 2 plasmid is used for preparing the medicine. A medicine for treating diabetic nephropathy is also disclosed and comprises the knockdown dynein light chain roadblock-type 2 plasmid. The medicine can be used for achieving novel, safe, effective and controllable gene therapy methods and for inhibiting TGF-beta mediated kidney fibrosis.

Description

technical field [0001] The invention relates to the application of dynein light chain barrier-2 type to prepare medicine for treating renal failure and the medicine. Background technique [0002] Renal fibrosis leads to end-stage renal failure, and since TGF-beta / Smad signaling regulates the expression of the extracellular matrix in renal disease, targeting TGF-beta signaling is an attractive therapeutic approach to control fibrosis. However, the complexity of the TGF-beta signaling pathway makes selecting appropriate therapeutic targets difficult. In particular, approaches targeting individual elements in the TGF-beta signaling pathway proved less useful. [0003] Over the past decade, many strategies to directly block the effects of TGF-beta have been developed, including the use of neutralizing antibodies to TGF-beta, oligodeoxynucleotides (ODNs) that suppress TGF-beta, soluble human TGF- Beta type II receptor, or specific inhibitor of TGF-beta receptor kinase. However...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K49/22A61P13/12A61P3/10
Inventor 钟志刚
Owner SHENZHEN RES INST THE CHINESE UNIV OF HONG KONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com